Polaryx Therapeutics (PLYX) Cash & Equivalents (2024 - 2026)

Polaryx Therapeutics (PLYX) has reported Cash & Equivalents for 3 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents changed N/A year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (changed N/A YoY), while the FY2025 annual figure was $5.1 million, up 11.3% from the prior year.
• Cash & Equivalents declined to $3.1 million in Q1 2026 per PLYX's latest filing, from $5.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $5.1 million in Q4 2025 and bottomed at $3.1 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $4.3 million across 3 years, with a median of $4.6 million in 2024.
• On a YoY basis, Cash & Equivalents climbed as much as 11.3% in 2025 and fell as far as 11.3% in 2025.
• Polaryx Therapeutics' Cash & Equivalents stood at $4.6 million in 2024, then advanced by 11.3% to $5.1 million in 2025, then plunged by 40.11% to $3.1 million in 2026.
• Business Quant data shows PLYX's Cash & Equivalents at $3.1 million in Q1 2026, $5.1 million in Q4 2025, and $4.6 million in Q4 2024.